ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
126.672,62
1,46%
S&P 500
6.124,80
0,16%
US Dollar vs BRL
5,7227
-0,79%
Bitcoin
96.856,04
0,25%
Brent Oil
74,71
-0,51%
As Melhores Corretoras Online
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NYSE
  6. Glaukos Corporation (GKOS)

  7. Glaukos Corporation (GKOS) Notícias

GKOS

Glaukos (GKOS)

Glaukos Corporation
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NYSE:GKOS
DataHoraFonteTítuloCódigoCompanhia
14/02/202512:13Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:GKOSGlaukos Corporation
12/02/202518:42Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NYSE:GKOSGlaukos Corporation
24/01/202520:33Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNYSE:GKOSGlaukos Corporation
23/01/202509:00Business WireGlaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20NYSE:GKOSGlaukos Corporation
14/01/202518:05Edgar (US Regulatory)Form 8-K - Current reportNYSE:GKOSGlaukos Corporation
14/01/202518:05Business WireGlaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical PlatformNYSE:GKOSGlaukos Corporation
02/01/202522:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:GKOSGlaukos Corporation
23/12/202409:00Business WireGlaukos Submits New Drug Application to U.S. FDA for Epioxa™NYSE:GKOSGlaukos Corporation
17/12/202409:00Business WireGlaukos Announces Participation in the J.P. Morgan Healthcare ConferenceNYSE:GKOSGlaukos Corporation
08/11/202409:00Business WireGlaukos Announces Participation in Upcoming Investor ConferencesNYSE:GKOSGlaukos Corporation
04/11/202418:05Business WireGlaukos Announces Third Quarter 2024 Financial ResultsNYSE:GKOSGlaukos Corporation
16/10/202417:05Business WireGlaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa™, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and SafetyNYSE:GKOSGlaukos Corporation
14/10/202408:00Business WireGlaukos To Present Multiple Scientific Abstracts at the 2024 American Academy of Ophthalmology Annual MeetingNYSE:GKOSGlaukos Corporation
09/10/202408:00Business WireGlaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4NYSE:GKOSGlaukos Corporation
02/08/202417:51Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NYSE:GKOSGlaukos Corporation
02/08/202417:44Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:GKOSGlaukos Corporation
31/07/202417:05Business WireGlaukos Announces Second Quarter 2024 Financial ResultsNYSE:GKOSGlaukos Corporation
10/07/202408:00Business WireGlaukos to Release Second Quarter 2024 Financial Results after Market Close on July 31NYSE:GKOSGlaukos Corporation
14/06/202408:00Business WireGlaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common StockNYSE:GKOSGlaukos Corporation
30/05/202417:45Edgar (US Regulatory)Form SD - Specialized disclosure reportNYSE:GKOSGlaukos Corporation
01/05/202417:05Business WireGlaukos Announces First Quarter 2024 Financial ResultsNYSE:GKOSGlaukos Corporation
16/04/202417:05Business WireGlaukos Announces the Release of its 2023 Sustainability ReportNYSE:GKOSGlaukos Corporation
10/04/202408:00Business WireGlaukos to Release First Quarter 2024 Financial Results after Market Close on May 1NYSE:GKOSGlaukos Corporation
03/04/202408:00Business WireGlaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)NYSE:GKOSGlaukos Corporation
01/04/202408:00Business WireGlaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual MeetingNYSE:GKOSGlaukos Corporation
04/03/202422:07Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NYSE:GKOSGlaukos Corporation
23/02/202419:23Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NYSE:GKOSGlaukos Corporation
21/02/202418:05Business WireGlaukos Announces Fourth Quarter and Full Year 2023 Financial ResultsNYSE:GKOSGlaukos Corporation
13/02/202419:41Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NYSE:GKOSGlaukos Corporation
31/01/202409:00Business WireGlaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21NYSE:GKOSGlaukos Corporation
 Apresentando as notícias mais relevantes sobre:NYSE:GKOS

Seu Histórico Recente

BIT
I09214
Intesa Sanpaolo
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios